These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Treatment of sickling disorders. Charache S Curr Opin Hematol; 1996 Mar; 3(2):139-44. PubMed ID: 9372064 [TBL] [Abstract][Full Text] [Related]
9. Addressing the crisis of care for sickle-cell disease. Morris K Lancet; 1999 May; 353(9163):1504. PubMed ID: 10232329 [No Abstract] [Full Text] [Related]
10. Hydroxyurea, sickle cell disease and renal transplantation. Allen A; Scoble J; Snowden S; Hambley H; Bellingham A Nephron; 1997; 75(1):106-7. PubMed ID: 9031282 [No Abstract] [Full Text] [Related]
11. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature]. Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961 [TBL] [Abstract][Full Text] [Related]
13. Pedigree analysis and involvement of peroxidase in sickle cell disease. Naqvi FN; Qasim S J Pak Med Assoc; 1992 Aug; 42(8):186-9. PubMed ID: 1331554 [TBL] [Abstract][Full Text] [Related]
14. New and experimental agents for sickle cell disease. Ataga KI Clin Adv Hematol Oncol; 2018 Jul; 16(7):476-479. PubMed ID: 30067617 [No Abstract] [Full Text] [Related]
15. The genomics of new drugs in sickle cell disease. Makis AC; Hatzimichael EC; Stebbing J Pharmacogenomics; 2006 Sep; 7(6):909-17. PubMed ID: 16981849 [TBL] [Abstract][Full Text] [Related]
16. Sickle cell disease: What all PAs should know. Kayinqo G JAAPA; 2012 Sep; 25(9):19-20. PubMed ID: 22991882 [No Abstract] [Full Text] [Related]
17. [How I treat ... sickle cell anemia: current therapies]. Rezaei Kalantari H Rev Med Liege; 2001 Oct; 56(10):671-5. PubMed ID: 11765575 [TBL] [Abstract][Full Text] [Related]
18. Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Gladwin MT; Rodgers GP Lancet; 2000 Apr; 355(9214):1476-8. PubMed ID: 10801164 [No Abstract] [Full Text] [Related]
19. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients. Chalikiopoulou C; Tavianatou AG; Sgourou A; Kourakli A; Kelepouri D; Chrysanthakopoulou M; Kanelaki VK; Mourdoukoutas E; Siamoglou S; John A; Symeonidis A; Ali BR; Katsila T; Papachatzopoulou A; Patrinos GP Pharmacogenomics; 2016 Mar; 17(4):393-403. PubMed ID: 26895070 [TBL] [Abstract][Full Text] [Related]